Meeting
2019 ASCO Annual Meeting
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
Authors
Joyce O'Shaughnessy
Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX
Joyce O'Shaughnessy , Martine Piccart , Lee S. Schwartzberg , Javier Cortes , Nadia Harbeck , Seock-Ah Im , Hope S. Rugo , Michael Untch , Denise A. Yardley , Igor Bondarenko , Stephen Chan , Veronique Dieras , Mark D. Pegram , Stew Kroll , Joseph P. O'Connell , Jeff Vacirca , Thomas Wei , Kevin Tang , Andrew David Seidman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03326674
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS1107)
DOI
10.1200/JCO.2019.37.15_suppl.TPS1107
Abstract #
TPS1107
Poster Bd #
184b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).
First Author: Joyce O'Shaughnessy
Poster
2021 ASCO Annual Meeting
Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.
First Author: Lee S. Schwartzberg
Poster
2018 ASCO Annual Meeting
Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.
First Author: Andrew David Seidman
Poster
2020 ASCO Virtual Scientific Program
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).
First Author: Sudpreeda Chainitikun